Neurology residency program at Cedars-Sinai wins accreditation

November 28, 2011

LOS ANGELES (Nov. 28, 2011) - The Accreditation Council for Graduate Medical Education has approved a neurology residency training program at Cedars-Sinai Medical Center. Recruitment of the first group of three residents is under way through the 2012 "match," a process in which an independent organization pairs applicants with programs to meet the preferences of each.

"With Cedars-Sinai's large and diverse patient population, our residents will have a chance to see a wide array of neurological disorders, including rare conditions. Their training will take place at a dynamic, growing campus that emphasizes efficient translation of research into clinical applications," said Nancy L. Sicotte, MD, director of the Neurology Residency Program and the Multiple Sclerosis Program in the Department of Neurology.

Residents in the three-year program, in inpatient and outpatient settings, will study with research and treatment experts in stroke; critical care; movement disorders; epilepsy; multiple sclerosis; headache; and neuromuscular disease. They will gain proficiency in electroencephalography, electromyography and other sophisticated techniques to study neurological conditions.

The program was designed to give residents increasing independence; elective time is built into the third year for focused research or more clinical expertise.

Sicotte said new programs and collaborations that will enhance residents' opportunities and learning experiences include: The residency program accreditation is the latest achievement in the Department of Neurology since Patrick D. Lyden, MD, joined Cedars-Sinai in 2009 as chair and the Carmen and Louis Warschaw Chair in Neurology. He is an internationally known researcher who is leading clinical trials of hypothermia to prevent brain injury following stroke. He was one of the key researchers in the major clinical trial leading to Food and Drug Administration approval in 1996 of tPA - tissue plasminogen activator - still the only proven, approved drug for stroke treatment.

On arrival, Lyden, an American Academy of Neurology fellow, bolstered the Movement Disorders Program by recruiting a world-renowned specialist, reinforced key existing programs and set the department on a course to expand its research, educational and clinical offerings. The department will relocate to the 450,000-square-foot Advanced Health Sciences Pavilion when it opens in 2013.

Sicotte, an American Academy of Neurology fellow, earned her medical degree from the University of California, Irvine, School of Medicine, and completed an internship in medicine, a residency in neurology and a fellowship in neuroimaging at UCLA. She has been active in educating residents, medical students and fellows and has directed courses at the annual American Academy of Neurology meeting. She has received the Harry Weaver Junior Faculty Award of the National Multiple Sclerosis Society and is researching multimodal imaging approaches to study multiple sclerosis.

Medical degree graduates must serve a one-year internship before their neurology residency. If Cedars-Sinai accepts applicants "outside of the match" who have already completed their internships, the first residents will begin training in July 2012. Otherwise, the inaugural group will start a year later, following the spring 2012 match and internships.
-end-


Cedars-Sinai Medical Center

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.